1. Scrip
  2. >>Business
  3. >>Commercial Strategy

In A Volatile Time, Pharma Reassures Business Remains Steady

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Amid a stock market freefall spurred largely by coronavirus uncertainty, big pharma sought to reassure investors and the public that supply disruptions are not an immediate concern and they are monitoring business operations day-by-day.

Businessman is riding on a roller coaster. Vector financial and economic crisis graph concept.
Stocks fell on a volatile day on Wall Street • Source: Shutterstock

Uncertainty around the coronavirus outbreak and an oil price war fueled a stock market sell off on 9 March that temporarily halted trading – and pharmaceutical stocks felt the blowback as much other industries. Drug ingredient supply disruptions, workforce health, manufacturing operations and global clinical trials are key concerns for the industry as COVID-19 spreads in Asia, Europe and the US.

The S&P 500 opened the day down 3.6%, the Dow Jones Industrial Average opened 3.3% lower, the Nasdaq composite index...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.